Vanguard Group Inc. Sells 103,146 Shares of Globus Medical, Inc. $GMED

Vanguard Group Inc. reduced its holdings in Globus Medical, Inc. (NYSE:GMED) by 1.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,605,747 shares of the medical device company’s stock after selling 103,146 shares during the quarter. Vanguard Group Inc. owned about 7.85% of Globus Medical worth $607,391,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of GMED. State of New Jersey Common Pension Fund D increased its holdings in shares of Globus Medical by 2.5% during the third quarter. State of New Jersey Common Pension Fund D now owns 39,035 shares of the medical device company’s stock valued at $2,236,000 after acquiring an additional 943 shares in the last quarter. Conscious Wealth Investments LLC grew its holdings in Globus Medical by 5.1% during the third quarter. Conscious Wealth Investments LLC now owns 49,052 shares of the medical device company’s stock worth $2,962,000 after buying an additional 2,364 shares in the last quarter. HighTower Advisors LLC lifted its stake in Globus Medical by 4.6% during the 3rd quarter. HighTower Advisors LLC now owns 40,466 shares of the medical device company’s stock valued at $2,317,000 after acquiring an additional 1,782 shares in the last quarter. Illinois Municipal Retirement Fund boosted its holdings in Globus Medical by 36.4% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 48,060 shares of the medical device company’s stock worth $2,752,000 after acquiring an additional 12,823 shares during the last quarter. Finally, Caprock Group LLC purchased a new stake in shares of Globus Medical during the third quarter valued at approximately $621,000. Institutional investors and hedge funds own 95.16% of the company’s stock.

Wall Street Analyst Weigh In

GMED has been the subject of a number of recent research reports. Needham & Company LLC upgraded shares of Globus Medical from a “hold” rating to a “buy” rating and set a $112.00 price objective for the company in a research note on Friday, January 30th. Citigroup reaffirmed a “market perform” rating on shares of Globus Medical in a research report on Thursday, January 8th. Zacks Research lowered Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 9th. Royal Bank Of Canada lifted their price objective on shares of Globus Medical from $92.00 to $100.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Finally, Bank of America upgraded Globus Medical from a “neutral” rating to a “buy” rating and upped their target price for the company from $65.00 to $91.00 in a research report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $100.18.

Globus Medical Stock Performance

Shares of GMED opened at $92.01 on Wednesday. The company’s 50-day simple moving average is $90.10 and its 200-day simple moving average is $75.84. Globus Medical, Inc. has a 1 year low of $51.79 and a 1 year high of $101.40. The stock has a market capitalization of $12.31 billion, a PE ratio of 29.68, a P/E/G ratio of 1.43 and a beta of 1.06.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.22. Globus Medical had a return on equity of 11.52% and a net margin of 15.30%.The company had revenue of $826.42 million for the quarter, compared to analyst estimates of $803.29 million. During the same quarter last year, the company posted $0.84 earnings per share. The business’s quarterly revenue was up 25.7% compared to the same quarter last year. On average, sell-side analysts predict that Globus Medical, Inc. will post 3.44 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Kelly Huller sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $87.67, for a total transaction of $876,700.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Leslie V. Norwalk sold 2,000 shares of the stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $101.10, for a total transaction of $202,200.00. Following the completion of the sale, the director owned 10,419 shares in the company, valued at $1,053,360.90. This represents a 16.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 34,136 shares of company stock valued at $3,111,033. Corporate insiders own 18.54% of the company’s stock.

Globus Medical News Roundup

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q4 revenue and non‑GAAP EPS beat expectations — Worldwide net sales were $826.4M (+25.7% YoY) and non‑GAAP diluted EPS was $1.28, ahead of consensus; the quarter showed strong margin expansion. GlobeNewswire
• Positive Sentiment: 2026 guidance and upgraded EPS outlook — Management reaffirmed 2026 revenue guidance of $3.18–$3.22B and raised non‑GAAP EPS guidance to $4.40–$4.50, a signal of confidence in continued margin leverage. GlobeNewswire
• Positive Sentiment: Analyst support — Multiple analysts maintained or raised bullish ratings/targets after results (Morgan Stanley reiterated Buy, PT $100; Needham reiterated Buy and raised its PT to $114), which can fuel further buying. TipRanks – Morgan Stanley TipRanks – Needham
• Neutral Sentiment: Acquisition-driven growth — Management credits integration of Nevro (and NuVasive earlier) for a big portion of incremental sales and EPS; that supports scale but raises questions about organic momentum. QuiverQuant summary
• Negative Sentiment: GAAP vs. non‑GAAP and sustainability concerns — GAAP diluted EPS ($1.03) is below the non‑GAAP number and some third‑party reports noted mixed EPS comparisons versus certain estimates; investors may discount non‑GAAP gains driven by acquisitions and one‑time items. QuiverQuant – EPS detail
• Negative Sentiment: Insider selling & cash reduction — Recent filings show multiple insider sales and cash & cash equivalents fell to ~$526M from ~$784M year‑over‑year, which could concern some investors about cash deployment and insider conviction. QuiverQuant – insider/cash

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.